The Experts below are selected from a list of 72087 Experts worldwide ranked by ideXlab platform
Jay W Heinecke - One of the best experts on this subject based on the ideXlab platform.
-
tertiary structure of Apolipoprotein a i in nascent high density lipoproteins
Proceedings of the National Academy of Sciences of the United States of America, 2018Co-Authors: Mohsen Pourmousa, Jere P Segrest, Hyun Deok Song, Yi He, Jay W Heinecke, Richard W PastorAbstract:Understanding the function of high-density lipoprotein (HDL) requires detailed knowledge of the structure of its primary protein, Apolipoprotein A-I (APOA1). However, APOA1 flexibility and HDL heterogeneity have confounded decades of efforts to determine high-resolution structures and consistent models. Here, molecular dynamics simulations totaling 30 μs on two nascent HDLs, each with 2 APOA1 and either 160 phospholipids and 24 cholesterols or 200 phospholipids and 20 cholesterols, show that residues 1–21 of the N-terminal domains of APOA1 interact via strong salt bridges. Residues 26–43 of one APOA1 in the smaller particle form a hinge on the disc edge, which displaces the C-terminal domain of the other APOA1 to the phospholipid surface. The proposed structures are supported by chemical cross-linking, Rosetta modeling of the N-terminal domain, and analysis of the lipid-free ∆185APOA1 crystal structure. These structures provide a framework for understanding HDL maturation and revise all previous models of nascent HDL.
-
methionine oxidation impairs reverse cholesterol transport by Apolipoprotein a i
Proceedings of the National Academy of Sciences of the United States of America, 2008Co-Authors: Baohai Shao, Michael N Oda, Giorgio Cavigiolio, Nathan Brot, Jay W HeineckeAbstract:HDL protects against vascular disease by accepting free cholesterol from macrophage foam cells in the artery wall. This pathway is critically dependent on lecithin:cholesterol acyltransferase (LCAT), which rapidly converts cholesterol to cholesteryl ester. The physiological activator of LCAT is Apolipoprotein A-I (apoA-I), the major HDL protein. However, cholesterol removal is compromised if apoA-I is exposed to reactive intermediates. In humans with established cardiovascular disease, myeloperoxidase (MPO) oxidizes HDL, and oxidation by MPO impairs apoA-I's ability to activate LCAT in vitro. Because a single methionine residue in apoA-I, Met-148, resides near the center of the protein's LCAT activation domain, we determined whether its oxidation by MPO could account for the loss of LCAT activity. Mass spectrometric analysis demonstrated that oxidation of Met-148 to methionine sulfoxide associated quantitatively with loss of LCAT activity in both discoidal HDL and HDL(3), the enzyme's physiological substrates. Reversing oxidation with methionine sulfoxide reductase restored HDL's ability to activate LCAT. Discoidal HDL prepared with apoA-I containing a Met-148-->Leu mutation was significantly resistant to inactivation by MPO. Based on structural data in the literature, we propose that oxidation of Met-148 disrupts apoA-I's central loop, which overlaps the LCAT activation domain. These observations implicate oxidation of a single Met in apoA-I in impaired LCAT activation, a critical early step in reverse cholesterol transport.
-
methionine oxidation impairs reverse cholesterol transport by Apolipoprotein a i
Proceedings of the National Academy of Sciences of the United States of America, 2008Co-Authors: Baohai Shao, Giorgio Cavigiolio, Nathan Brot, Jay W HeineckeAbstract:Abstract HDL protects against vascular disease by accepting free cholesterol from macrophage foam cells in the artery wall. This pathway is critically dependent on lecithin:cholesterol acyltransferase (LCAT), which rapidly converts cholesterol to cholesteryl ester. The physiological activator of LCAT is Apolipoprotein A-I (apoA-I), the major HDL protein. However, cholesterol removal is compromised if apoA-I is exposed to reactive intermediates. In humans with established cardiovascular disease, myeloperoxidase (MPO) oxidizes HDL, and oxidation by MPO impairs apoA-I's ability to activate LCAT in vitro. Because a single methionine residue in apoA-I, Met-148, resides near the center of the protein's LCAT activation domain, we determined whether its oxidation by MPO could account for the loss of LCAT activity. Mass spectrometric analysis demonstrated that oxidation of Met-148 to methionine sulfoxide associated quantitatively with loss of LCAT activity in both discoidal HDL and HDL3, the enzyme's physiological substrates. Reversing oxidation with methionine sulfoxide reductase restored HDL's ability to activate LCAT. Discoidal HDL prepared with apoA-I containing a Met-148→Leu mutation was significantly resistant to inactivation by MPO. Based on structural data in the literature, we propose that oxidation of Met-148 disrupts apoA-I's central loop, which overlaps the LCAT activation domain. These observations implicate oxidation of a single Met in apoA-I in impaired LCAT activation, a critical early step in reverse cholesterol transport. atherosclerosis dysfunctional HDL hypochlorous acid inflammation methionine sulfoxide reductase
-
lysine residues direct the chlorination of tyrosines in yxxk motifs of Apolipoprotein a i when hypochlorous acid oxidizes high density lipoprotein
Journal of Biological Chemistry, 2004Co-Authors: Constanze Bergt, Nabiha P Huq, Jeff Kao, Jay W HeineckeAbstract:Oxidized lipoproteins may play an important role in the pathogenesis of atherosclerosis. Elevated levels of 3-chlorotyrosine, a specific end product of the reaction between hypochlorous acid (HOCl) and tyrosine residues of proteins, have been detected in atherosclerotic tissue. Thus, HOCl generated by the phagocyte enzyme myeloperoxidase represents one pathway for protein oxidation in humans. One important target of the myeloperoxidase pathway may be high density lipoprotein (HDL), which mobilizes cholesterol from artery wall cells. To determine whether activated phagocytes preferentially chlorinate specific sites in HDL, we used tandem mass spectrometry (MS/MS) to analyze Apolipoprotein A-I that had been oxidized by HOCl. The major site of chlorination was a single tyrosine residue located in one of the protein's YXXK motifs (where X represents a nonreactive amino acid). To investigate the mechanism of chlorination, we exposed synthetic peptides to HOCl. The peptides encompassed the amino acid sequences YKXXY, YXXKY, or YXXXY. MS/MS analysis demonstrated that chlorination of tyrosine in the peptides that contained lysine was regioselective and occurred in high yield if the substrate was KXXY or YXXK. NMR and MS analyses revealed that the N(epsilon) amino group of lysine was initially chlorinated, which suggests that chloramine formation is the first step in tyrosine chlorination. Molecular modeling of the YXXK motif in Apolipoprotein A-I demonstrated that these tyrosine and lysine residues are adjacent on the same face of an amphipathic alpha-helix. Our observations suggest that HOCl selectively targets tyrosine residues that are suitably juxtaposed to primary amino groups in proteins. This mechanism might enable phagocytes to efficiently damage proteins when they destroy microbial proteins during infection or damage host tissue during inflammation.
Philip J Barter - One of the best experts on this subject based on the ideXlab platform.
-
Apolipoprotein a i improves pancreatic β cell function independent of the atp binding cassette transporters abca1 and abcg1
The FASEB Journal, 2019Co-Authors: Liming Hou, Shudi Tang, Kwok Leung Ong, Marit Westerterp, Philip J Barter, Blake J Cochran, Fatiha Tabet, Kerryanne RyeAbstract:Apolipoprotein A-I (apoA-I), the main protein constituent of HDLs, increases insulin synthesis and insulin secretion in pancreatic β cells. ApoA-I also accepts cholesterol that effluxes from cells expressing ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1). Mice with conditional deletion of ABCA1 and ABCG1 in β cells [β-double knockout (DKO) mice] have increased islet cholesterol levels and reduced glucose-stimulated insulin secretion (GSIS). The project asks whether metabolic pathways are dysregulated in β-DKO mouse islets and whether this can be corrected, and GSIS improved, by treatment with apoA-I. β-DKO mice were treated with apoA-I or PBS, and islets were isolated for determination of GSIS. Total RNA was extracted from β-DKO and control mouse islets for microarray analysis. Metabolic pathways were interrogated by functional enrichment analysis. ApoA-I treatment improved GSIS in β-DKO but not control mouse islets. Plasma lipid and lipoprotein levels and islet cholesterol levels were also unaffected by treatment with apoA-I. Cholesterol metabolism, glucose metabolism, and inflammation pathways were dysregulated in β-DKO mouse islets. This was not corrected by treatment with apoA-I. In summary, apoA-I treatment improves GSIS by a cholesterol-independent mechanism, but it does not correct metabolic dysregulation in β-DKO mouse islets.-Hou, L., Tang, S., Wu, B. J., Ong, K.-L., Westerterp, M., Barter, P. J., Cochran, B. J., Tabet, F., Rye, K.-A. Apolipoprotein A-I improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1.
-
association of high density lipoprotein cholesterol versus Apolipoprotein a i with risk of coronary heart disease the european prospective investigation into cancer norfolk prospective population study the atherosclerosis risk in communities study and the women s health study
Journal of the American Heart Association, 2017Co-Authors: Julian C Van Capelleveen, Matthijs S Boekholdt, Philip J Barter, Andrea E Bochem, Samia Mora, Ron C Hoogeveen, Christie M Ballantyne, Paul M Ridker, Wensheng Sun, Alan R TallAbstract:BackgroundThe contribution of Apolipoprotein A‐I (apoA‐I) to coronary heart disease (CHD) risk stratification over and above high‐density lipoprotein cholesterol (HDL‐C) is unclear. We studied the ...
-
the impact of glycation on Apolipoprotein a i structure and its ability to activate lecithin cholesterol acyltransferase
Diabetologia, 2007Co-Authors: E Nobecourt, Michael J Davies, Bronwyn E Brown, Linda K Curtiss, David J Bonnet, Francesca Charlton, Andrzej S Januszewski, Alicia J Jenkins, Philip J BarterAbstract:Aims/hypothesis Hyperglycaemia, one of the main features of diabetes, results in non-enzymatic glycation of plasma proteins, including Apolipoprotein A-I (apoA-I), the most abundant Apolipoprotein in HDL. The aim of this study was to determine how glycation affects the structure of apoA-I and its ability to activate lecithin:cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport.
Matthijs S Boekholdt - One of the best experts on this subject based on the ideXlab platform.
-
association of high density lipoprotein cholesterol versus Apolipoprotein a i with risk of coronary heart disease the european prospective investigation into cancer norfolk prospective population study the atherosclerosis risk in communities study and the women s health study
Journal of the American Heart Association, 2017Co-Authors: Julian C Van Capelleveen, Matthijs S Boekholdt, Philip J Barter, Andrea E Bochem, Samia Mora, Ron C Hoogeveen, Christie M Ballantyne, Paul M Ridker, Wensheng Sun, Alan R TallAbstract:BackgroundThe contribution of Apolipoprotein A‐I (apoA‐I) to coronary heart disease (CHD) risk stratification over and above high‐density lipoprotein cholesterol (HDL‐C) is unclear. We studied the ...
-
high density lipoprotein cholesterol high density lipoprotein particle size and Apolipoprotein a i significance for cardiovascular risk the ideal and epic norfolk studies
Journal of the American College of Cardiology, 2008Co-Authors: Wim A Van Der Steeg, Erik S.g. Stroes, Ingar Holme, Matthijs S Boekholdt, Mogens Lytken Larsen, Christina Lindahl, Matti J Tikkanen, Nicholas J Wareham, Ole Faergeman, Anders G OlssonAbstract:Objectives: This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and Apolipoprotein A-I (apoA-I) with the occurrence of coronary ar ...
-
role of the Apolipoprotein b Apolipoprotein a i ratio in cardiovascular risk assessment a case control analysis in epic norfolk
Annals of Internal Medicine, 2007Co-Authors: Wim A Van Der Steeg, Erik S.g. Stroes, Matthijs S Boekholdt, Nicholas J Wareham, Evan A Stein, K Elharchaoui, Manjinder S Sandhu, Wouter J Jukema, Robert Luben, Aeilko H ZwindermanAbstract:The Apolipoprotein B–Apolipoprotein A-I (apo B–apo A-I) ratio is a strong risk factor for atherosclerotic cardiovascular disease. The researchers performed a case–control analysis of persons 45 to ...
Anders G Olsson - One of the best experts on this subject based on the ideXlab platform.
-
high density lipoprotein cholesterol high density lipoprotein particle size and Apolipoprotein a i significance for cardiovascular risk the ideal and epic norfolk studies
Journal of the American College of Cardiology, 2008Co-Authors: Wim A Van Der Steeg, Erik S.g. Stroes, Ingar Holme, Matthijs S Boekholdt, Mogens Lytken Larsen, Christina Lindahl, Matti J Tikkanen, Nicholas J Wareham, Ole Faergeman, Anders G OlssonAbstract:Objectives: This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and Apolipoprotein A-I (apoA-I) with the occurrence of coronary ar ...
Wim A Van Der Steeg - One of the best experts on this subject based on the ideXlab platform.
-
high density lipoprotein cholesterol high density lipoprotein particle size and Apolipoprotein a i significance for cardiovascular risk the ideal and epic norfolk studies
Journal of the American College of Cardiology, 2008Co-Authors: Wim A Van Der Steeg, Erik S.g. Stroes, Ingar Holme, Matthijs S Boekholdt, Mogens Lytken Larsen, Christina Lindahl, Matti J Tikkanen, Nicholas J Wareham, Ole Faergeman, Anders G OlssonAbstract:Objectives: This study was designed to assess the relationship of high-density-lipoprotein cholesterol (HDL-C), HDL particle size, and Apolipoprotein A-I (apoA-I) with the occurrence of coronary ar ...
-
role of the Apolipoprotein b Apolipoprotein a i ratio in cardiovascular risk assessment a case control analysis in epic norfolk
Annals of Internal Medicine, 2007Co-Authors: Wim A Van Der Steeg, Erik S.g. Stroes, Matthijs S Boekholdt, Nicholas J Wareham, Evan A Stein, K Elharchaoui, Manjinder S Sandhu, Wouter J Jukema, Robert Luben, Aeilko H ZwindermanAbstract:The Apolipoprotein B–Apolipoprotein A-I (apo B–apo A-I) ratio is a strong risk factor for atherosclerotic cardiovascular disease. The researchers performed a case–control analysis of persons 45 to ...